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incidence
Ovarian cancer is the ninth most common cancer in women
(excluding skin cancer). It ranks fifth as the cause of cancer
death in women. A woman’s risk of getting invasive ovarian
cancer in her lifetime is about 1 in 71 and the lifetime risk of
dying from invasive ovarian cancer is about 1 in 95. In the
United States, 21 550 new cases and 14 600 deaths are
estimated annually. There are, however, large variations in the
incidence of ovarian cancer in different areas of the world; in
the European Union the estimated number of newly diagnosed
cases was 42 700 in 2004 with a mortality of 12/100 000
women/year. The majority of these deaths were from ovarian
cancer of the serous histological type and around half of
women who are diagnosed with ovarian cancer are 60 or older.
Ovarian cancer is therefore an important public health issue in
Western countries, although >50% of new cases diagnosed
every year worldwide occur in developing countries.
Several risk factors have been correlated with ovarian cancer,
such as obesity, talcum powder use and certain fertility drugs,
but none has been so strongly correlated as poor reproductive
history and duration of reproductive career. Early menarche
and late menopause seem to increase the risk of ovarian cancer.
Another important risk factor for ovarian cancer is genetic
predisposition in fact women who carry BRCA1 or BRCA2
mutations have an estimated lifetime risk of between 60% and
85% of developing breast cancer, and a lifetime risk of between
26% and 54% of developing ovarian cancer for BRCA1, and
between 10% and 23% for BRCA2. The factors associated with
a decreased risk of ovarian cancer are the use of oral
contraceptives, breastfeeding, bilateral tubal ligation or
hysterectomy, prophylactic oophorectomy.
pathology
traditional pathological approach
Approximately 90% of primary malignant ovarian tumours are
epithelial (carcinomas). Most are thought to arise from the
ovarian surface epithelium or Mullerian derivatives including the
distal Fallopian tube; peritoneal tumours of ovarian type are
staged as ovarian primaries. The World Health Organization
(WHO) classification of ovarian tumours recognizes six major
histotypes (serous, mucinous, endometrioid, clear cell,
transitional cell and squamous). Tumours of each type are
further subdivided into three prognostically relevant categories
(benign, malignant and intermediate, the latter known as
tumours of borderline malignancy or low malignant potential
and atypical proliferative tumours). According to their
architectural features, carcinomas are classified into three grades
corresponding to percentage (<5%, 5%–50% and >50%) of solid
growth on glandular and papillary component, by the FIGO
(International Federation of Gynecology and Obstetrics) system.
At present, it is recognized that a universal, multifactorial
grading system for all ovarian carcinomas is difficult to apply.
recent advances
With the recognition of relevant subtypes and refinement of
prognostic criteria, there is now evidence that ovarian cancer
represents a group of distinct entities with distinct types of
carcinogenesis, which should benefit from a more specific
approach.
Overall, the most significant advances are the following:
 Mucinous tumours consist of two subgroups, the so-called
endocervical-like (seromucinous or Mullerian) mucinous
tumours, usually in the borderline category and similar to
borderline serous tumours, and the intestinal type, the latter
being the more common. In this subtype, pathological studies
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are very important in distinguishing between metastatic
carcinoma from the upper gastrointestinal tract (including
biliary tract), pancreas and cervix, and primary ovarian
mucinous tumour.
 Borderline tumours are considered precursors of serous
carcinoma following the identification of low-grade serous
carcinomas, which account for those carcinomas occurring in
association with or in the follow-up of borderline tumours.
Borderline tumours can also less frequently be mucinous, and
rarely endometrioid.
 In high-grade serous carcinomas, grading is no longer
considered reproducible and prognostically useful following
the recognition that low-grade serous carcinoma is a distinct
type of tumour.
conventional high-grade serous carcinoma and
low-grade serous carcinoma
Approximately 80%–85% of all ovarian carcinomas in Western
countries are serous. Up to 95% of patients with FIGO stage
III–IV disease have serous carcinomas, while FIGO stage I
serous carcinomas are very uncommon.
Serous carcinomas typically show papillary, micropapillary
architecture and solid growth with typical slit-like spaces;
glandular, cribriform and trabecular features, which are more
common in non-serous carcinomas, may also occur. Recent
pathological and molecular studies suggest that the secretory
epithelium cells of the Fallopian tube may be the site of origin
for high-grade serous ovarian tumours in the hereditary
ovarian cancer setting.
The rare low-grade serous carcinomas are characterized by
low grade of cell atypia and low mitotic activity in the range of
epithelial changes of borderline tumours.
endometrioid and clear cell carcinoma
Endometrioid carcinomas have decreased in prevalence,
accounting for the second most common ovarian carcinoma
subtype (10% of all ovarian carcinomas). Clear cell carcinomas
are 5% of all ovarian carcinomas and are particularly common
only in Japanese women. Most endometrioid and clear cell
carcinomas are FIGO stage I or II and endometrioid carcinoma
is the most common tumour in FIGO stage I.
transitional cell carcinoma
Carcinomas with transitional-like features are quite common;
however, most are papillary high-grade tumours with
histological features and immunofenotype (expression of WT1
and p53) in the range of serous carcinomas.
other carcinomas
A group of tumours designated as Mullerian mucinous or
endocervical-like mucinous or seromucinous or mixed
epithelial neoplasms with a mucinous component
characteristically demonstrate the low-power appearance of
serous borderline tumours. The lesional cells are a mixture of
endocervical-type cells with apical mucin (but not goblet cells),
ciliated cells and so-called indifferent cells. These tumours
typically show an association with endometriosis. Many
undifferentiated carcinomas of ovarian surface epithelium
origin behave as high-grade serous carcinomas.
molecular correlation and pathogenetic approach
The subclassification proposed by Kurman, based on pathology
and genetics, consists of two groups designated type I and type
II. Type I tumours include those that arise from well-
characterized precursor lesions, specifically borderline tumours;
some have a variable behaviour (mucinous, endometrioid and
clear cell carcinomas) while others are slowly growing
neoplasms (low-grade serous carcinomas). Type I tumours
show a number of different mutations (including KRAS, BRAF,
PTEN and b-catenin) and are relatively genetically stable. Low-
grade serous carcinomas and their precursor lesions, serous
borderline tumours, are characterized by mutually exclusive
sequence mutations in KRAS, BRAF and ERBB2 oncogenes.
Mutations of KRAS and BRAF seem to occur very early in the
development of low-grade serous borderline tumours, since
the same KRAS and BRAF mutations detected in serous
borderline tumours were present in the cystadenoma
epithelium adjacent to the serous borderline component.
Mutations of KRAS and BRAF have been reported in 10% of
endometrioid carcinomas, mutation of PTEN in another 20%.
Similar molecular genetic alterations, including loss of
heterozygosity at 10q23 and PTEN mutations, have been
observed in endometriosis, atypical endometriosis and ovarian
endometrioid carcinoma in the same specimen. Mutations in
KRAS and PTEN instability have been reported in clear cell
carcinoma.
Type II tumours, on the contrary, are high grade, biologically
aggressive tumours that do not have a recognized precursor
lesion and are thought to arise de novo from coelomic
epithelium; the prototype is serous carcinoma: included in this
group are high-grade transitional carcinomas, malignant mixed
mesodermal tumours (MMMTs) and undifferentiated
carcinomas. Type II tumours show considerable genetic
instability and TP53 mutations, while the mutations
characteristic of type I tumours are not detected. Hereditary
cancers with BRCA1 and BRCA2 mutations belong to type II
tumours.
diagnosis
The most frequent symptoms are abdominal discomfort or
vague pain, abdominal fullness, bowel habit changes, early
satiety, dyspepsia and bloating. The presence of a pelvic mass at
clinical evaluation is an important sign of possible ovarian
cancer. Occasionally, patients may present with bowel
obstruction due to intra-abdominal masses or shortness of
breath due to pleural effusion. In early stage disease, the patient
may complain of irregular menses if she is premenopausal; if
a pelvic mass is compressing the bladder or rectum, the patient
may report urinary frequency and/or constipation. Occasionally,
the patient may perceive lower abdominal distention, pressure
or pain, such as dyspareunia; acute symptoms, such as a pain
secondary to rupture or torsion, are unusual.
In advanced stage disease, patients most often have
symptoms related to ascites and abdominal distension due to
masses. The symptoms include abdominal distention, bloating,
constipation, nausea, anorexia or early satiety. In stage IV
disease, shortness of breath due to pleural effusion is also
reported. If nodal metastases are present, enlarged inguinal,
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supraclavicular and axillary nodes may be palpated. The serum
CA125 level has been widely used as a marker for a possible
epithelial ovarian cancer in the primary assessment of a suspect
adnexal mass. In this setting, false-positive results may derive
from several conditions, in particular those associated with
peritoneal inflammation, such as endometriosis, adenomyosis,
pelvic inflammatory disease, menstruation, uterine fibroids or
benign cysts. In a retrospective analysis of serum samples from
5550 women who were enrolled in a population-based registry
in Sweden, 175 women had elevated CA125 values. Ovarian
cancer was ultimately diagnosed in six of these women and also
developed in three women with normal CA125 values. The
specificity of the test was 98.5% for women over the age of 50
years but was lower (94.5%) for those who were younger than
50 (i.e. it had a low positive predictive value). As compared
with women with an elevated CA125 value in whom ovarian
cancer was not diagnosed, the women who ultimately were
found to have ovarian cancer were more likely to have
progressive elevation of the CA125 value over time.
Transvaginal ultrasonography is often included among the
procedures for the evaluation of a pelvic mass. Features highly
suggestive of advanced ovarian cancer are the presence of
a complex ovarian mass, with both solid and cystic
components, sometimes with internal echoes and/or septations,
ascites or evidence of peritoneal metastases in the presence of
an ovarian mass. The use of multimodal screening (serum
CA125 measurement and ultrasound imaging) for early
detection of ovarian cancer seems to be effective. In a large
randomized controlled trial a total of 202 638 post-menopausal
women (aged between 50 and 74 years) were randomly assigned
to no treatment, annual CA125 screening with transvaginal
ultrasound scan as a second-line test or annual screening with
transvaginal ultrasound alone. The study showed that the use of
CA125 with ultrasound scan has a higher specificity than
transvaginal ultrasound alone to detect primary ovarian and
tubal cancers. Despite these promising results, multimodal
screening is not considered yet the gold standard for early
detection of ovarian cancer. Further randomized controlled
studies are needed to demonstrate the impact of multimodal
screening on survival of patients with ovarian cancer. Other
imaging techniques, such as magnetic resonance imaging
(MRI) or positron emission tomography (PET), may provide
additional information but are not routinely necessary in
preoperative evaluation. The goal of imaging in ovarian cancer
detection is to expeditiously distinguish benign adnexal lesions
from those requiring further pathological evaluation for
malignancy. For lesions indeterminate on ultrasound, MRI
increases the specificity of the imaging evaluation, thus
decreasing benign resections. CT is useful in diagnosis and
treatment planning of advanced cancer. Although FDG-avid
ovarian lesions in postmenopausal women are considered
suspicious for malignancy, PET/CT is not recommended for
primary cancer detection because of high false-positive rates.
staging and risk assessment
Surgical staging requires a laparotomy by a midline incision for
adequate exposure and careful examination of the abdominal
cavity according to the FIGO guidelines (Table 1). If disease
Table 1. Staging of cancer of the ovary
Stage I Growth limited to the ovaries
IA Growth limited to one ovary; no ascites present
containing malignant cells. No tumour on
the external surface; capsule intact
IB Growth limited to both ovaries; no ascites
present containing malignant cells. No
tumour on the external surfaces; capsules
intact
ICa Tumour either stage IA or IB, but with tumour
on surface of one or both ovaries, or with
capsule ruptured, or with ascites present
containing malignant cells, or with positive
peritoneal washings
Stage II Growth involving one or both ovaries with
pelvic extension
IIA Extension and/or metastases to the uterus and/
or tubes
IIB Extension to other pelvic tissues
IICa Tumour either stage IIA or IIB, but with
tumour on surface of one or both ovaries, or
with capsule(s) ruptured, or with ascites
present containing malignant cells, or with
positive peritoneal washings
Stage III Tumour involving one or both ovaries with
histologically confirmed peritoneal implants
outside the pelvis and/or positive regional
lymph nodes. Superficial liver metastases
equal stage III. Tumour is limited to the true
pelvis, but with histologically proven
malignant extension to small bowel or
omentum
IIIA Tumour grossly limited to the true pelvis, with
negative nodes, but with histologically
confirmed microscopic seeding of
abdominal peritoneal surfaces, or histologic
proven extension to small bowel or
mesentery
IIIB Tumour of one or both ovaries with
histologically confirmed implants, peritoneal
metastasis of abdominal peritoneal surfaces,
none exceeding 2 cm in diameter; nodes are
negative
IIIC Peritoneal metastasis beyond the pelvis >2 cm
in diameter and/or positive regional lymph
nodes
Stage IV Growth involving one or both ovaries with
distant metastases. If pleural effusion is
present, there must be positive cytology to
allot a case to stage IV. Parenchymal liver
metastasis equals stage IV
aIn order to evaluate the impact on prognosis of the different criteria for
allotting cases to stage IC or IIC, it would be of value to know whether rupture
of the capsule was spontaneous, or caused by the surgeon and whether the
source of malignant cells detected was peritoneal washings or ascites.
Reprinted with permission by the International Federation of Gynecology and
Obstetrics (FIGO): Odicino F, Pecorelli S, Zigliani L, Creasman WT. History
of the FIGO cancer staging system. Int J Gynecol Obstet 2008; 101: 205–210
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appears confined to the ovary, staging procedures include
biopsy of the diaphragmatic peritoneum, paracolic gutters,
pelvic peritoneum, complete or selected lymphadenectomy of
the pelvic and para-aortic lymph nodes, infracolic,
omentectomy, four washings of the peritoneal cavity
(diaphragm, right and left sides of the abdomen and pelvis);
total abdominal hysterectomy and bilateral salpingo-
oophorectomy (BSO); appendectomy for mucinous tumours.
Surgical staging studies of apparent early stage ovarian
cancers have confirmed that up to 22% of patients will have
their disease upstaged. Young et al. performed a systematic
restaging in 100 consecutive patients operated elsewhere and
initially assessed as having stage I or II ovarian cancer. In 31
(31%) of 100 patients, the stage was higher, and 23 (77%) of
the 31 patients had stage III disease. Sites of unsuspected
disease were most likely to be pelvic peritoneum, ascites fluid,
other pelvic tissues, para-aortic nodes and diaphragm.
The importance of performing pelvic and para-aortic lymph
node dissection is due to the high rate of nodal involvement in
patients with apparent stage I or II. Cass and colleagues showed
in 96 patients with gross disease confined to one ovary, that
15% had microscopically positive lymph nodes. Among these
patients, 50% had positive pelvic nodes, 36% had positive para-
aortic node and both were positive in 14% of the cases. All
these patients were grade 3. In the case of advanced disease
retroperitoneal dissection is not routinely performed and the
prognostic benefits remain controversial. Benedetti Panici et al.
conducted a randomized clinical trial to determine the impact
of systematic aortic and pelvic lymphadenectomy on
progression-free (PFS) and overall survival (OS) comparing
with resection of bulky nodes only in stage IIIB–C and IV
epithelial ovarian carcinoma patients. The authors
demonstrated that systematic lymphadenectomy improved PFS
but not OS [I].
Staging should be carried out by an appropriately trained
surgeon with experience in the management of ovarian cancer.
Most general surgeons are unfamiliar with retroperitoneal
anatomy in the pelvis, particularly around the side wall and
blood vessels. The evidence demonstrates that the performance
of an adequate surgical staging is most likely to be not
‘correctly’ performed by a general surgeon (65%) rather than
a general gynaecologist (48%).
Primary cytoreductive surgery is the standard approach to
initial treatment of patients with advanced ovarian cancer.
Theoretically, there are good reasons to believe that tumour
debulking will increase survival. In fact, tumour reduction
before chemotherapy may synchronize cell division, improve
drug availability to metastases, reduce the number of cycles of
chemotherapy required to eradicate residual disease and
diminish development of subsequent drug resistance. Bristow
et al. evaluated 81 studies involving 6885 patients and
demonstrated that each 10% increase in the number of patients
receiving maximal cytoreduction was associated with a 5.5%
increase in median survival. Furthermore, the prognosis of
patients with suboptimal tumour debulking surgery remains
poor. In patients in whom optimal debulking is not feasible,
interval debulking surgery should be considered; in fact
several retrospective studies have demonstrated a decreased
morbidity with acceptable survival rate. In 1995, the
Gynecological Cancer Cooperative Group (GCG) of the
European Organization for Research and Treatment of
Cancer (EORTC) showed in a prospective randomized study
that interval debulking surgery significantly lengthens PFS
and OS.
Approximately 15% of epithelial ovarian cancer is diagnosed
as stage IV disease. Overall, median survival for patients with
stage IV disease is 15–23 months with an estimated 5-year
survival of 20%. A retrospective analysis of 360 patients with
stage IV who underwent primary surgery followed by
chemotherapy [six cycles of intravenous (i.v.) platinum/
paclitaxel] showed that patients with microscopic residual
tumour after surgery had the best outcome whereas patients
with 0.1–1.0 cm residual disease and patients with 1.1–5.0 cm
residual disease had similar PFS and OS. Furthermore, ultra-
radical cytoreduction might be justified in selected cases if
microscopic residual tumour can be achieved.
primary treatment
early disease: FIGO stage I–IIa
In patients with disease apparently confined to the pelvis
and absence of extra-abdominal metastatic disease, surgical
staging is essential to provide better prediction of outcome
and it is an independent prognostic factor for survival
influencing ongoing management.
Total abdominal hysterectomy and BSO with omentectomy,
peritoneal washing, peritoneal biopsies, evaluation of the entire
abdominal cavity and retroperitoneal assessment that involves
both the pelvic and para-aortic area should be performed.
In selected patients who desire to preserve their childbearing
potential, unilateral salpingo-oophorectomy with adequate
staging may be performed after proper counselling.
With the advent of minimally invasive surgical techniques,
surgeons are now able to perform all the necessary procedures
for comprehensive surgical staging by laparoscopy or robotics,
including laparoscopic pelvic and para-aortic
lymphadenectomy and omentectomy. Large studies evaluating
disease-free interval and OS are needed before concluding that
laparoscopic staging of early stage ovarian cancer is preferable
to laparotomy.
prognostic factors
Classic clinical and pathological prognostic factors, such as
degree of differentiation, FIGO stage, histological type, large
volume of ascites, rupture before surgery, extracapsular growth
and age of the patient, have been identified by multivariate
analyses as independent prognostic factors in epithelial ovarian
cancer.
Vergote et al. in a large series of patients with early stage
ovarian cancer showed that the degree of differentiation was the
most powerful prognostic indicator of disease-free survival.
This was followed by rupture before surgery, rupture during
surgery bilaterality of the tumour and age.
Based on these prognostic factors, optimally staged tumours
can be classified as at low, medium or high risk for recurrence.
Low risk includes stage IA–IB grade 1 tumour; medium risk
includes stage IA and IB grade 2; high risk includes stage IC all
grades, IB or IC grades 2 and 3, clear cell histology.
clinical practice guidelines Annals of Oncology
v26 | Colombo et al. Volume 21 | Supplement 5 |May 2010
chemotherapy
Adjuvant chemotherapy for early stage ovarian cancer remains
a controversial topic.
A recent meta-analyses of 5 large prospective clinical trials
(4 of 10 with platinum-based chemotherapy) showed that
chemotherapy is more beneficial than observation in patients
with early stage ovarian cancer. The patients who received
platinum-based adjuvant chemotherapy had better OS [hazard
ratio (HR) 0.71; 95% confidence interval (CI) 0.53–0.93] and
PFS (HR 0.67; 95% CI 0.53–0.84) than patients who did not
receive adjuvant treatment. Even though two-thirds of the
patients included in the two major studies were suboptimally
staged, some benefit for chemotherapy in optimally staged
patients cannot be excluded. Therefore, it seems wise to
conclude that adjuvant chemotherapy should be offered not
only to suboptimally staged patients but also to optimally
staged medium or high-risk patients.
The optimal duration of treatment remains controversial; in
fact only one randomized trial (GOG 157) showed that six
cycles of carboplatin and paclitaxel were not associated with
longer PFS and OS, but with a significantly greater toxicity than
three cycles.
Therefore, based on meta-analysis data, we recommend six
cycles of single-agent carboplatin as adjuvant treatment in patients
with intermediate and high-risk early stage ovarian cancer.
Advanced disease; FIGO stages IIb–IIIc
Stage IIb were included in the advanced stage group because,
according to Figo classification, ovarian cancer involves other
pelvic tissues with a consequent worsening of prognosis; the
reported 5-year survival rate is from 71%–90% in early to 65%
in Figo stage IIb.
The standard initial treatment of advanced ovarian cancer
consists of cytoreductive surgery followed by a combination
platinum-based chemotherapy.
Since 1986 the threshold of £1 cm residual disease in greatest
dimension has been used to define ‘optimal’ cytoreduction; an
additional survival advantage of cytoreduction to no visible
residual disease has been recently reported.
A literature review showed that patients with optimal
cytoreduction had a median survival of 39 months as compared to
that of 17 months of patients with suboptimal residual disease.
Several studies have consistently shown that specialized
surgeons, namely gynecological oncologists, are more likely to
perform optimal surgery than general surgeons.
If initial maximal cytoreduction is not carried out, interval
debulking surgery (IDS) should be considered in patients
responding to chemotherapy or with stable disease [II, B]. IDS
should ideally be carried out after three cycles of chemotherapy,
followed by three further cycles of the same chemotherapy [III].
chemotherapy
After surgical cytoreduction, the treatment of choice for patients
with advanced epithelial ovarian cancer is platinum-based
chemotherapy.
Since 1996 the combination of platinum plus paclitaxel has
been the standard treatment; in fact the GOG 111 study
demonstrated statistically significant outcome advantages for
the combination of cisplatin plus paclitaxel compared to the
standard regimen of cyclophosphamide plus cisplatin in
patients with previously untreated advanced stage III and IV
disease. Subsequently, cisplatin was replaced by carboplatin, in
view of the GOG 114 results, in which carboplatin, compared
with cisplatin, showed equivalent outcomes with less toxicity
and better administration [I].
Long-term follow-up in the GOG 111 and OV.10 studies
demonstrated PFS in only 18% of patients at 6 years. Efforts to
improve these poor long-term outcomes have resulted in
a variety of experimental strategies, such as the addition of
a third, potentially non-cross-resistant, cytotoxic agent to
a platinum/taxane doublet in various schedules.
The largest phase III Gynecologic Cancer Intergroup (GCIG)
trial (GOG 0182-ICON 5) enrolled 4312 patients into a
5-arm protocol. Each arm included eight cycles of triplet
(carboplatin–paclitaxel–gemcitabine and carboplatin–
paclitaxel–liposomal doxorubicin), or sequential-doublet
chemotherapy, which provided a minimum of four cycles with
the experimental treatments (carboplatin–topotecan and
carboplatin–gemcitabine) while maintaining at least four cycles
with carboplatin and paclitaxel, or eight cycles of standard
treatment (carboplatin–paclitaxel). There was absolutely no
statistically significant superiority or clinically useful benefit
associated with the three drugs compared with the control
arm [I].
Currently, there are no data to recommend any new two- or
three-drug combination and carboplatin–paclitaxel still
remains the treatment of choice.
Three randomized trials analysed the impact of the duration
of chemotherapy (i.e. number of cycles) on OS. None of these
studies demonstrated a difference in median survival time, but
longer durations were associated with more toxicity, expecially
neuropathy. These studies were the basis for the current
rationale for six cycles of treatment as the convention.
Epithelial ovarian cancer arises from the epithelial surface of
the ovary with intra-abdominal spread to the peritoneal cavity
confined to the abdomen.
The intraperitoneal (IP) administration of chemotherapy
offers the possibility of targeting therapy to the site of disease
while minimizing systemic toxicities. The result of the GOG
172 study, which prompted the NCI announcement in January
2006, showed that IP therapy was associated with longer
survival in surgically treated optimal ovarian cancer patients
added to i.v. therapy as compared with i.v. therapy alone (65.6
versus 49.7 months of median survival with a 21.6% reduction
in death). However, the study raised concern about IP therapy’s
toxicity and tolerability, since less than half of patients
completed the planned experimental treatment (42% of 205
eligible patients).
A recent meta-analysis showed that the hazard ratio for PFS
of IP cisplatin as compared with i.v. treatment regimens is
0.792 (95% CI;: 0.688–0.912; P = 0.001), and the HR for OS is
0.799 (95% CI 0.702–0.910; P = 0.0007). These findings
support the incorporation of an IP cisplatin regimen in the
front-line treatment of stage III, optimally debulked ovarian
cancer. The trade-off between survival and tolerability sets
the stage for a future large intergroup phase III trial
evaluating IP therapy in first-line treatment of advanced
ovarian cancer [I].
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treatment of recurrent disease
Appropriate salvage therapy is based on the timing and nature
of the recurrence and the extent of prior chemotherapy.
Surgical resection should be considered in platinum-sensitive
patients with prolonged treatment free-interval (e.g. >24
months), especially with isolated recurrence and good
performance status. A recent meta-analysis showed that one of
the most important predictors of survival in patients
undergone secondary cytoreduction is the complete
cytoreduction; in fact, each 10% increase in the proportion of
patients undergoing complete cytoreductive surgery was
associated with a 3.0 month increase in median cohort survival
time. However, the role of aggressive secondary surgery is only
supported by retrospective or prospective non-randomized
studies; randomized trials are clearly needed to strongly
support the advantages of secondary surgery. In general,
patients who progress during treatment with platinum are
considered to have ‘platinum-refractory’ disease, patients who
develop recurrence <6 months from the completion of first-line
platinum chemotherapy are considered to have ‘platinum-
resistant’ disease and those with an interval >6 months
‘platinum-sensitive’ disease.
Patients experiencing a durable response to platinum
induction chemotherapy have a high probability of responding
again to platinum-containing compounds. The choice between
cisplatin and carboplatin should be based on the agent used in
previous therapy, its tolerability and residual toxicity. In order
to determine whether the combination carboplatin and
paclitaxel should be used at first relapse after platinum-based
chemotherapy, two pragmatic trials were designed. ICON4 and
OVAR 2.2 were two parallel randomized trials comparing
a minimum of six cycles of platinum chemotherapy versus
paclitaxel plus platinum in 802 patients relapsing after
platinum-based chemotherapy (almost 50% of the patients
received platinum–paclitaxel combination) with a treatment-
free interval of >6 months (OVAR 2.2) or >12 months
(ICON4). The HR for progression was 0.77 and the HR for
survival is 0.77 in favour of paclitaxel–platinum combination
(P = 0.006). There was no evidence that the effect was larger or
smaller in any subgroups (randomization group, time to
relapse, number of previous lines of chemotherapy, type of
prior chemotherapy, age and performance status). These results
suggest that the combination improves survival and PFS in
patients with ‘platinum-sensitive’ relapsed ovarian cancer
compared with platinum alone [I].
In general, ovarian cancer patients relapsing after first-line
platinum–paclitaxel therapy are at risk of significant
neurotoxicity when retreated with the same regimen within up
to 12 months from the end of first chemotherapy due to
cumulative neurotoxicity of both carboplatin and paclitaxel.
The frequency of clinically significant residual neurotoxicity
after first-line chemotherapy was part of the rationale for
evaluating an active platinum-based combination not
associated with this toxic effect. The AGO-OVAR study showed
that there was a significant improvement in PFS and response
rate without a worsening of quality of life in 356 platinum-
sensitive patients who received six courses of gemcitabine and
carboplatin combination versus carboplatin alone. PFS in the
combination arm and in the single-agent arm was, respectively,
8.6 months (95% CI 7.9–9.7) and 5.8 months (95% CI 5.2–7.1)
(P = 0.0031); response rate was 47.2% in the combination arm
and 30.9% in the single-agent arm. No statistically significant
differences in OS were observed.
A multicentre phase III study has been recently presented at
the annual meeting of the ASCO comparing efficacy and safety
of carboplatin–pegylated liposomal doxorubicin and
carboplatin–paclitaxel in 976 relapsed platinum-sensitive
ovarian cancer patients. The trial showed non-inferiority of the
experimental arm in terms of PFS (11.3 months versus 9.4;
HR= 0.821, 95% CI 0.72–0.94; P = 0.005) with lower rates of
severe and long-lasting toxicity. This treatment could become
the new standard in patients with similar disease characteristics.
Salvage chemotherapy in platinum-refractory patients
typically results in low response rates and short survival
(C). Rechallenge with platinum-based treatments produces
a response rate of 10%, while the response rate of drugs with
antitumour activity in paclitaxel–platinum-refractory disease
(topotecan, docetaxel, oral etoposide, liposome encapsulated
doxorubicin, gemcitabine, ifosfamide and
hexamethylmelamine) is 10%. Since the achievement of
durable response is rare and cure almost impossible, the main
goal of salvage therapy in this group of patients is palliation;
therefore, particular attention should be paid to the side-effects
of the drugs used. Patients with good performance status and
motivated to receive further treatment should be considered for
experimental trials with new drugs.
Palliative secondary surgery should be considered to relieve
intestinal obstruction in patients who have failed two or more
chemotherapy regimens. The criteria for selection of patients
for palliative surgery are categorized according to the
presumptive estimate of duration of survival, the overall
medical status and performance status, presence of ascites, the
will to live, presence of focal disease and a suspicion of local
obstruction where a bypass or local resection might be feasible.
follow-up
Follow-up after primary therapy in ovarian cancer is poorly
defined. History, physical examination including pelvic
examination every 3 months for 2 years, every 4 months during
the third year and every 6 months during years 4 and 5 or until
progression is documented.
The serum assay of CA125 during chemotherapy is used to
evaluate the response to the treatment. According to GCIG
criteria, progression or recurrence based on serum CA125 levels
is defined on the basis of a progressive serial elevation of serum
CA125. Elevated values must be confirmed by two separate
measurements obtained at least 1 week apart. CA125 progression
will be assigned the date of the first measurement that meets the
criteria as noted. Patients are not assessable by CA125 if they
have received mouse antibodies or if there has been medical and/
or surgical interference with their peritoneum or pleura during
the previous 28 days.
The serum assay of CA125 is an adequate toll for the
follow-up of responders after the completion of chemotherapy
since it has been shown to be predictive of ovarian cancer
relapse.
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With early detection of recurrence, patients often begin
treatment before symptoms manifest themselves, but the data
available on the efficacy of this procedure are not conclusive. At
ASCO 2009 the results of a large phase III randomized study,
evaluating whether there were clinical benefits from the early
start of treatment, based on increased CA125 antigen, versus
a delay of treatment up to the onset of clinical manifestations of
the disease, were presented. The study involved 527 patients in
complete remission after first-line platinum-based
chemotherapy and with normal CA125 level at study entry.
Patients randomized to immediate chemotherapy started
second-line treatment 4.8 months earlier and third-line
treatment 4.6 months earlier than the patients in the delayed-
therapy group. With a median follow-up of 49 months and 351
deaths, there was no evidence of difference in OS between
immediate and delayed treatment (HR = 1.01; 95% CI 0.82–
1.25; P = 0.91). Quality of life was lower in the early-treatment
group, presumably because this group was exposed to more
extensive chemotherapy and had a longer duration of
treatment.
The conclusions were that there is no benefit from early
detection of relapse by routine CA125 measurement and that,
even if CA125 rises, chemotherapy can be delayed until signs or
symptoms of tumour recurrence [I]. However, it is important
to offer women informed choices in follow-up and keep in
mind that a potentially resectable occult macroscopic
recurrence can be signalled by a CA125 rise.
CT scans should be performed if there is clinical or CA125
evidence for progressive disease. However, from data in the
literature, PET-CT scans seem to be superior to CT scans in
detecting more sites of tumour, especially nodal, peritoneal and
subcapsular liver disease. If a patient is considered for surgery,
PET scan allows a more accurate selection of cases potentially
candidates for secondary surgery.
note
Levels of Evidence [I–V] and Grades of Recommendation [A–
D] as used by the American Society of Clinical Oncology are
given in square brackets. Statements without grading were
considered justified standard clinical practice by the expert
authors and the ESMO faculty.
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